SEC Filing Summary: Intrexon Corporation (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation on June 5, 2015. The report addresses a special dividend distribution of ZIOPHARM Oncology, Inc. common stock to Intrexon shareholders and warrant holders. The record date for the distribution was June 4, 2015.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a stock distribution event.
Material Changes and Events
- Special Dividend Announcement: Intrexon finalized the distribution ratio for an aggregate of 17,830,305 shares of ZIOPHARM Oncology, Inc. common stock.
- Distribution Ratio: Holders of Intrexon common stock will receive 0.162203 shares of ZIOPHARM common stock for each Intrexon share owned as of the close of business on the Record Date.
- Warrant Holders: Holders of Warrants relating to Intrexon common stock will receive 0.162203 shares of ZIOPHARM common stock for each share of Intrexon common stock deliverable under the Warrants.
- Timing: The distribution is expected to occur on or about June 12, 2015.
Guidance, Outlook, and Risks
Intrexon announced the concurrent filing of an Information Statement (Exhibit 99.2) which contains a description of ZIOPHARM, details of the distribution, and certain U.S. federal income tax consequences. The filing does not provide forward-looking financial guidance or discuss operational risks beyond the tax implications noted in the attached Information Statement.
Key Facts for Investor Verification
- Verify the exact number of Intrexon shares and Warrants held as of the June 4, 2015 Record Date to calculate the total ZIOPHARM shares receivable.
- Review the attached Information Statement (Exhibit 99.2) for specific U.S. federal income tax consequences of the distribution.
- Confirm the actual distribution date, which is expected to be on or about June 12, 2015.
- Note that the registrant name in the filing header is Intrexon Corporation, despite the request metadata referencing Precigen, Inc.